SKK
ACHN

Shepherd Kaplan Krochuk’s Achillion Pharmaceuticals ACHN Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-23,514
Closed -$208K – 479
2015
Q2 		$208K Hold
23,514
– – 0.04% 302
2015
Q1 		$232K Hold
23,514
– – 0.04% 271
2014
Q4 		$288K Buy
23,514
+4,680
+25% +$57.2K 0.05% 283
2014
Q3 		$188K Buy
+18,834
New +$175K 0.02% 446

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Shepherd Kaplan Krochuk's ACHN Position: Q3 2015 in Review

Shepherd Kaplan Krochuk sold out of Achillion Pharmaceuticals (ACHN) in Q3 2015, closing a stake of 23,514 shares — an estimated $208K sold.

Shepherd Kaplan Krochuk first reported a position in ACHN in Q3 2014 and held it in 4 quarters. The position peaked at $288K in Q4 2014. 141 funds tracked by Wall St. Rank hold ACHN as of Q3 2015.

  • Shepherd Kaplan Krochuk reported no remaining Achillion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 23,514 Achillion Pharmaceuticals shares in Q3 2015, an estimated $208K.
  • Shepherd Kaplan Krochuk first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 4 quarters.
  • Shepherd Kaplan Krochuk's Achillion Pharmaceuticals position peaked at $288K in Q4 2014.
  • 141 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2015.

Based on Shepherd Kaplan Krochuk's 13F filing for Q3 2015, filed 16 Nov 2015.